- Tumors1000+
- Pathology985
- Pathologic Processes953
- Cancer936
- Nervous System Diseases816
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathology985
- Pathologic Processes953
- Cancer936
- Nervous System Diseases816
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR positive
- EGFR negative
- PD-L1 negative
- BRAF positive
- PR positive
- ER negative
- ALK negative
- PR negative
- KRAS positive
- ALK positive
- BRAF negative
- p16 positive
- CD20 positive
- MET positive
- BRCA1 positive
- HR positive
- IDH positive
- BRCA2 positive
- HLA-A positive
- ROS1 negative
- PIK3CA positive
- ROS1 positive
- IDH negative
- TP53 positive
- HLA positive
- MYC positive
- dMMR positive
- BCR-ABL1 positive
- MSI-H positive
- NTRK positive
- RET positive
- p16 negative
- BRCA positive
- FLT3 positive
- HPV positive
- MET negative
- RAS positive
- anti-dsDNA positive
- ANA positive
- CD123 positive
- HPV negative
- NF1 positive
- PALB2 positive
- BCL2 positive
- FGFR2 positive
- HBsAg positive
- HLA negative
- NTRK negative
- RAS negative
- RET negative
- TP53 negative
- BCL6 positive
- CCND1 positive
- FGFR positive
- HLA-A negative
- KRAS negative
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSS positive
- NRAS positive
- PMS2 positive
- RB1 negative
- RB1 positive
- ctDNA positive
- ABCA4 positive
- CD19 positive
- CFTR positive
- CLDN18.2 positive
- KIT positive
- KMT2A positive
- L858R positive
- MGMT negative
- MMR positive
- NTRK1 positive
- PD-1 positive
- PTEN positive
- Philadelphia Chromosome positive
- RAF positive
- RF positive
- TROP2 negative
- TROP2 positive
- anti-Sm positive
- pMMR positive
- APC positive
- APP positive
- ATM positive
- BRCA1 negative
- BRCA2 negative
- CD22 positive
- CD30 positive
- COL7A1 positive
- EBV positive
- Ex19del positive
- FMR1 positive
- HBV DNA positive
- HEXA positive
- HEXB positive
- HPV16 positive
- HbSS positive
- JAK2 positive
- Ki67 positive
- MDM2 positive
- MGMT positive
- MMR negative
- MSI positive
- MSI-H negative
- NF2 positive
- PD-1 negative
- PKLR positive
- PSEN1 positive
- PSEN2 positive
- RHO positive
- SMN1 positive
- SPINK5 positive
- TSC1 positive
- TSC2 positive
- anti-Ro autoantibodies positive
- dMMR negative
- t(11;14) positive
- \-17/abn(17p) positive
- \-5/del(5q) positive
- \-7 positive
- 11q negative
- 11q positive
- AKT negative
- ALPL positive
- Anti-Smith positive
- Aβ1-42 positive
- C5 positive
- CD5 positive
- COL1A1 positive
- COL1A2 positive
- Complex karyotype positive
- DLL3 positive
- DMD positive
- DMPK positive
- EZH2 positive
- FAP positive
- FGFR1 positive
- FGFR3 positive
- FLT3 negative
- FOXO1 fusion negative
- GATA2 positive
- GPC3 positive
- GRN positive
- H3K27M positive
- HBB positive
- HBV DNA negative
- HBsAg negative
- HR negative
- HRAS positive
- HRD positive
- IDS positive
- IGHV positive
- KMT2A-r positive
- LKB1 positive
- MECOM positive
- MECP2 positive
- MSI negative
- MSS negative
- NPM1 positive
- NRAS negative
- PDE6A positive
- PDE6B positive
- PDGFRA positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PMM2 positive
- PTCH1 positive
- PTEN negative
- PiZZ positive
- RAF negative
- SMARCA4 positive
- SSTR positive
- STK11 positive
- T315I positive
- T790M positive
- TMB positive
- TTR positive
- ZnT8 positive
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- anti-Ro/SSA positive
- del(17p) positive
- inv(3)(q21.3q26.2) positive
- other sickle cell syndrome variants positive
- p53 positive
- t(14;16) positive
- t(3;3)(q21.3;q26.2) positive
- t(4;14) positive
- t(9;11) positive
- 11q23 positive
- 12 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Adjuvant Radiation Therapy
- Adjuvant Therapy (except reconstruction)
- Allogeneic Hematopoietic Cell Transplantation
- Anti-Seizure Medications (up to 2 types)
- Any Treatment Intervention Resulting in Improvement in Fatigue and Physical Function
- Any Treatment for Pancreatic Cancer
- Archival Tissue Block or Newly-Obtained Core Needle or Incisional Biopsy
- At least one prior tumor-directed therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
5464 trials
1
2
3
…50